Absence of human papillomavirus infection and activation of pi3k-akt pathway in cervical clear cell carcinoma

International Journal of Gynecological Cancer

Volumn 23, Issue 6, 2013, Pages 1084-1091

  Ueno, Sayaka ^a   Sudo, Tamotsu ^a,b   Oka, Noriko ^b   Wakahashi, Senn ^a   Yamaguchi, Satoshi ^a   Fujiwara, Kiyoshi ^a   Mikami, Yoshiki ^c   Nishimura, Ryuichiro ^a  

^a Department of Gynecologic Oncology ^*  (United States)

^b HYOGO CANCER CENTER   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

AKT pathway; Clear cell carcinoma of the cervix; EGFR; HER2; HPV

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENOMIC DNA; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INCIDENCE; CANCER RECURRENCE; CANCER STAGING; CANCER THERAPY; CASE REPORT; CERVICAL CLEAR CELL CARCINOMA; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK FACTORS; SIGNAL TRANSDUCTION; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; UTERINE CERVICAL NEOPLASMS;

EID: 84880322531     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182981bdc     Document Type: Article

References (30)

1. Bray F, Carstensen B, Moller H, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev. 2005;14:2191-2199.
2. Sherman ME, Wang SS, Carreon J, et al. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer. 2005;103: 1258-1264.
3. Castellsague X, Diaz M, de Sanjose S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: Implications for screening and prevention. J Natl Cancer Inst. 2006;98:303-315.
4. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer. 2003;88:63-73.
5. Herbst AL. DES-associated clear cell adenocarcinoma of the vagina and cervix. Obstet Gynecol Surv. 1979;34:844.
6. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971;284:878-881.
7. Hanselaar A, van Loosbroek M, Schuurbiers O, et al. Clear cell adenocarcinoma of the vagina and cervix. An update of the central Netherlands registry showing twin age incidence peaks. Cancer. 1997;79:2229-2236.
8. Noordhuis MG, Eijsink JJ, Ten Hoor KA, et al. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res. 2009;15:7389-7397.
9. Kersemaekers AM, Fleuren GJ, Kenter GG, et al. Oncogene alterations in carcinomas of the uterine cervix: Overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res. 1999;5:577-586.
10. Kihana T, Tsuda H, Teshima S, et al. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer. 1994;73:148-153.
11. Nakano T, Oka K, Ishikawa A, et al. Correlation of cervical carcinoma c-erbB-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma. Cancer. 1997;79:513-520.
12. Kim TJ, Lee JW, Song SY, et al. Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer. 2006;94:1678-1682.
13. Lee CM, Shrieve DC, Zempolich KA, et al. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol. 2005;99:415-421.
14. Fujinaga Y, Shimada M, Okazawa K, et al. Simultaneous detection and typing of genital human papillomavirus DNA using the polymerase chain reaction. J Gen Virol. 1991;72:1039-1044.
15. Sotlar K, Diemer D, Dethleffs A, et al. Detection and typing of human papillomavirus by e6 nested multiplex PCR. J Clin Microbiol. 2004;42:3176-3184.
16. Nakanishi T, Ishikawa H, Suzuki Y, et al. A comparison of prognoses of pathologic stage Ib adenocarcinoma and squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 2000;79:289-293.
17. Thomas MB, Wright JD, Leiser AL, et al. Clear cell carcinoma of the cervix: A multi-institutional review in the post-DES era. Gynecol Oncol. 2008;109:335-339.
18. Kocken M, Baalbergen A, Snijders PJ, et al. High-risk human papillomavirus seems not involved in DES-related and of limited importance in nonDES related clear-cell carcinoma of the cervix. Gynecol Oncol. 2011;122:297-302.
19. Park KJ, Kiyokawa T, Soslow RA, et al. Unusual endocervical adenocarcinomas: An immunohistochemical analysis with molecular detection of human papillomavirus. Am J Surg Pathol. 2011;35:633-646.
20. Pirog EC, Kleter B, Olgac S, et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol. 2000;157:1055-1062.
21. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297:813-819.
22. Konno R, Tamura S, Dobbelaere K, et al. Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study. Cancer Sci. 2011;102:877-882.
23. Miura S, Matsumoto K, Oki A, et al. Do we need a different strategy for HPV screening and vaccination in East Asia? Int J Cancer. 2006;119:2713-2715.
24. Hadzisejdc I, Krasevic M, Haller H, et al. Distribution of human papillomavirus types in different histological subtypes of cervical adenocarcinoma. Coll Antropol. 2007;31:97-102.
25. Waggoner SE, Anderson SM, Van Eyck S, et al. Human papillomavirus detection and p53 expression in clear-cell adenocarcinoma of the vagina and cervix. Obstet Gynecol. 1994;84:404-408.
26. Crook T, Wrede D, Tidy JA, et al. Clonal p53 mutation in primary cervical cancer: Association with human-papillomavirus-negative tumours. Lancet. 1992;339:1070-1073.
27. Missaoui N, Hmissa S, Frappart L, et al. p16INK4A overexpression and HPV infection in uterine cervix adenocarcinoma. Virchows Arch. 2006;448:597-603.
28. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11:6422-6430.
29. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol. 2006;24:5601-5608.
30. del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: A review of the literature. Gynecol Oncol. 2012;126:481-490.